RARE DISEASERESEARCH ATLAS

ORPHA:231393

Beta-thalassemia-X-linked thrombocytopenia syndrome

medium confidenceDisorder

Also known as: XLTT

Query health: suspect — Only one of 3 strategies returned hits (phrase).

Publications

5

12.1th percentile

Trials

0

Interventional, condition-specific

Researchers

27

Distinct authors in sample

Gene link

GATA1

Moderate

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Beta-thalassemia - X-linked thrombocytopenia is a form of beta-thalassemia characterized by and petechiae, moderate thrombocytopenia, prolonged bleeding time due to platelet dysfunction, reticulocytosis and mild beta-thalassemia.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

X-linked thrombocytopenia with Beta-thalassemia · thrombocytopenia with beta-thalassemia, X-linked, X-linked recessive

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Moderate — GATA1

  2. LiteraturePresent

    5 matched papers (2 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Probably — there is moderate evidence for GATA1.

GenCC classification: Moderate.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

5

5 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

5 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

2 in the last 10 years · medium confidence · 12.1th percentile (publications denominator)

Phrase hits: 5 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

27

Distinct author names in 5 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Adenaeuer A1 paper · 2022

    Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.

    Papers in Europe PMC
  2. 02
    Bergmann F1 paper · 2022

    Coagulation Laboratory, MVZ Wagnerstibbe, Amedes-Group, 30159 Hanover, Germany.

    Papers in Europe PMC
  3. 03
    Cantor AB1 paper · 2005

    Division of Pediatric Hematology/Oncology, Children's Hospital Boston, Boston, Massachusetts 02115, USA. alan.cantor@childrens.harvard.edu

    Papers in Europe PMC
  4. 04
    Crispino JD1 paper · 2009
    Papers in Europe PMC
  5. 05
    Czwalinna A1 paper · 2022

    Coagulation Laboratory, MVZ Wagnerstibbe, Amedes-Group, 30159 Hanover, Germany.

    Papers in Europe PMC
  6. 06
    Dore LC1 paper · 2009
    Papers in Europe PMC
  7. 07
    Dupuis A1 paper · 2016

    UMR_S949, INSERM, Strasbourg, France Etablissement Français du Sang-Alsace (EFS-Alsace), Strasbourg, France Université de Strasbourg, France Fédération de Médecine Translationnelle de Strasbourg (FMTS), France.

    Papers in Europe PMC
  8. 08
    Erkel J1 paper · 2022

    Pediatric Department, St. Marienhospital, 49377 Vechta, Germany.

    Papers in Europe PMC
  9. 09
    Feng G1 paper · 2009
    Papers in Europe PMC
  10. 10
    Fritsch N1 paper · 2022

    Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Beta-thalassemia-X-linked thrombocytopenia syndrome" OR "X-linked thrombocytopenia with Beta-thalassemia" OR "thrombocytopenia with beta-thalassemia, X-linked, X-linked recessive"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Thrombocytopenia, Platelet Dysfunction, Hemolysis, and Imbalanced Globin Synthesis

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Beta-thalassemia-X-linked thrombocytopenia syndrome" OR "X-linked thrombocytopenia with Beta-thalassemia" OR "thrombocytopenia with beta-thalassemia, X-linked, X-linked recessive" OR "Thrombocytopenia, Platelet Dysfunction, Hemolysis, and Imbalanced Globin Synthesis" OR "GATA1" OR "beta-thalassemia and related diseases" OR "GATA1-Related X-Linked Cytopenia"

Recall-expansion terms: GATA1, beta-thalassemia and related diseases, GATA1-Related X-Linked Cytopenia

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: XLTT

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T10:16:56.735Z